TITLE

Toksoplazma Koryoretinitine İkincil Koroidal Neovasküler Membran Olgusunda İntravitreal Bevacizumab Enjeksiyon Tedavisi

AUTHOR(S)
Güngör, Sirel Gür; Akkoyun, İmren; Şingar, Evin; Yılmaz, Gürsel
PUB. DATE
May 2014
SOURCE
Turkish Journal of Ophthalmology / Turk Oftalmoloji Dergisi;5/1/2014, Vol. 44 Issue 3, p237
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
A 57-year-old male patient presenting with visual loss in the left eye was diagnosed as choroidal neovascular membrane secondary to inactive toxoplasmosis retinochoroiditis scar. He underwent intravitreal bevacizumab injection as primary therapy. The choroidal neovascular membrane regressed partially and the initial visual acuity improved from 1/10 to 3/10. Intravitreal bevacizumab injection appears to be effective in the treatment of choroidal neovascular membrane secondary to toxoplasma retinochoroiditis.
ACCESSION #
111530167

 

Related Articles

  • Bevacizumab.  // Reactions Weekly;3/12/2011, Issue 1342, p9 

    The article describes two cases of fibrotic retinal changes following treatment with bevacizumab for supposed choroidal neovascular membrane.

  • Bevacizumab (Avastin) as a surgical adjunct in diabetic vitrectomy for fibrovascular disease. Gandhi, J. S.; Tan, L. T.; Pearce, I.; Charles, S. J. // Eye;Mar2009, Vol. 23 Issue 3, p742 

    A letter to the editor is presented which discusses the effectiveness of bevacizumab in reducing the vascularity membranes before diabetic vitrectomy.

  • Ä°ntravitreal Bevacizumab Uygulamasının Erken Dönem Göz İçi Basıncına Etkisi. Özçalışkan, Şehnaz; Yılmazbaş, Pelin; Öztürk, Faruk; Beyazyıldız, Özlem // Turkish Journal of Ophthalmology / Turk Oftalmoloji Dergisi;Sep/Oct2014, Vol. 44 Issue 5, p361 

    Bevacizumab, göz içi basıncı, intravitreal enjeksiyon Objectives: To evaluate the short-term intraocular pressure (IOP) changes after intravitreal injection of 0.05 mL (1.25 mg) bevacizumab. Materials and Methods: The study included 57 eyes of 57 patients who had an intravitreal...

  • Bevacizumab.  // Reactions Weekly;5/5/2012, Issue 1400, p11 

    The article describes the case of a 69-year-old man who experienced membranous nephropathy following treatment with intravitreal bevacizumab for macular degeneration.

  • Bevacizumab.  // Reactions Weekly;7/14/2007, Issue 1160, p11 

    The article describes the case of a 74-year-old man who developed a retinal pigment epithelial tear following his second intravitreal bevacizumab injection. He received bevacizumab after pneumatic displacement of subretinal blood. He also underwent macular translocation with 360° retinotomy...

  • Intracameral injection of bevacizumab (Avastin) to treat anterior chamber neovascular membrane in a painful blind eye. Raghuram, A.; Saravanan, V. R.; Narendran, V. // Indian Journal of Ophthalmology;Nov2007, Vol. 55 Issue 6, p460 

    Intracameral injection of bevacizumab (Avastin) helped in the successful regression of an anterior chamber neovascular membrane in a painful blind eye. The effect was persistent even after six months of follow-up. This is the first report on intracameral administration of bevacizumab with six...

  • Treatment of peripapillary choroidal neovascular membranes with intravitreal bevacizumab. Figueroa, M. S.; Noval, S.; Contreras, I. // British Journal of Ophthalmology;Sep2008, Vol. 92 Issue 9, p1244 

    Aims: To evaluate the effect of intravitreal injections of bevacizumab in the treatment of peripapiltary choroidal neovascular membranes. Methods: Interventional case series of patients with active peripapillary choroidal neovascular membranes. Ophthalmological examination included...

  • Submacular hemorrhage secondary to congenital toxoplasmosis. de Azevedo Costa, Ana Luiza Fontes; Santos Martins, Thiago Gonçalves dos; Solano Moncada, Francisco Javier; Santos Motta, Mário Martins dos // Einstein (16794508);Jan-Mar2014, Vol. 12 Issue 1, p106 

    We report the case of a patient with congenital toxoplasmosis and submacular hemorrhage caused by a neovascular membrane who underwent an intravitreal injection of C3F8 and bevacizumab, and had a good visual recovery.

  • Bevacizumab/ranibizumab.  // Reactions Weekly;5/22/2010, Issue 1302, p13 

    The article presents the case of four elderly patients who developed ocular hypertension following intravitreal injections of bevacizumab or rabinizumab for choroidal neovascular membrane (CNVM) secondary to age-related macular degeneration (AMD)

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics